**HPTN 083**

**Active Products**
Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
4,570 cisgender men and transgender women who have sex with men

**Locations**
Argentina, Brazil, Peru, South Africa, Thailand, U.S., Vietnam

**Start Date**
December 2016

**Study Design**
Non-Inferiority of CAB LA to TDF/FTC
A non-inferiority study tests whether one drug works about the same as, but not worse than, another drug.

**Study Phases**

**PHASE 1**
5 weeks of 2 daily oral pills – 1 active and 1 placebo

**PHASE 2**
Injections every 8 weeks and daily pills for up to 3 years

**PHASE 3**
Daily oral pills for up to 1 year

**HPTN 084**

**Active Products**
Long-acting injectable cabotegravir (CAB LA), oral cabotegravir (CAB), oral TDF/FTC

**Populations**
3,200 (projected) cisgender women

**Locations**
Botswana, Eswatini, Kenya, Malawi, South Africa, Uganda, Zimbabwe

**Start Date**
November 2017

**Study Design**
Superiority of CAB LA to TDF/FTC
A superiority study tests whether one drug works better than another drug.

**Study Phases**

**PHASE 1**
5 weeks of 2 daily oral pills – 1 active and 1 placebo

**PHASE 2**
Injections every 8 weeks and daily pills for up to 3.5 years

**PHASE 3**
Daily oral pills for up to 1 year

= placebo